BCMU
PLX icon

BlueCrest Capital Management (UK)’s Protalix BioTherapeutics PLX Stock Holding History

BlueCrest Capital Management (UK)’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-7,300
Closed -$334K – 693
2014
Q1 		$334K Buy
+7,300
New +$341K 0.02% 405

Other funds holding PLX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MTWSIF
Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

BlueCrest Capital Management (UK)'s PLX Position: Q2 2014 in Review

BlueCrest Capital Management (UK) sold out of Protalix BioTherapeutics (PLX) in Q2 2014, closing a stake of 7,300 shares — an estimated $334K sold.

BlueCrest Capital Management (UK) first reported a position in PLX in Q1 2014 and held it in 1 quarter. The position peaked at $334K in Q1 2014. 45 funds tracked by Wall St. Rank hold PLX as of Q2 2014.

  • BlueCrest Capital Management (UK) reported no remaining Protalix BioTherapeutics position as of Q2 2014 after selling out during the quarter.
  • BlueCrest Capital Management (UK) sold 7,300 Protalix BioTherapeutics shares in Q2 2014, an estimated $334K.
  • BlueCrest Capital Management (UK) first reported a position in Protalix BioTherapeutics in Q1 2014 and held it in 1 quarter.
  • BlueCrest Capital Management (UK)'s Protalix BioTherapeutics position peaked at $334K in Q1 2014.
  • 45 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2014.

Based on BlueCrest Capital Management (UK)'s 13F filing for Q2 2014, filed 15 Aug 2014.